Application for new drug for green leaf pharmaceutical injection leipaketone reprieve microsphere (LY03004) accepted by the National Drug Review Center

Recently, theGroup of Green leafPharmaceutical(http:// announced that its independent research and development of innovative preparation "injectable lypeone re-release microsphere (LY03004)"new drug(http://application (NDA) has been accepted by the China NationalMedicines(http://Regulatory Authority Drug Review CenterAbout LY03004
LY03004 is used to treat schizophrenia, with intramuscular injections every two weeksThe clinical results show that LY03004 has good safety and, after reaching a steady state, achieves bioequivalentwith another commercially availabledrug(http:// and http://LY03004 can improve the prevalence of oral antipsychotic drugs in patients with schizophrenia, and will simplify the course of treatment of schizophreniaCompared to another commercially available drug, LY03004 has several advantages, such as the need for patients to take oral preparations three weeks after their first injection, and to achieve steady-state blood concentrations faster than those sold in the cityIn addition to LY03004, several other research projects have been developed simultaneously in China and overseas markets, including the injection of Rotidein reprieve microspheres (LY03003) for the treatment of Parkinson's disease, and the hydrochloric acid Anshufasin reprieve (LY) for the treatment of depression 03005), palmacid palaeonone reprieve injection (LY03010) for the treatment of schizophrenia and split-emotional disorders, and the Mindo-Day Transderating Patch (LY30410) for the treatment of Alzheimer's diseaseThe above-mentionedProduct(http://is well registered in thepharmaceutical(http://markets in China, the United States, Europe and Japan, and Greenleaf Pharmaceuticals is also ready for the global market launch of LY03004 and subsequent new drugs